Biopharmaceutical Informatics (eBook)

Learning to Discover Developable Biotherapeutics

Autor: Sandeep (Hrsg.) Kumar

CHF 175.45

ISBN: 978-1-040-27382-1

Einband: PDF

Verfügbarkeit: Noch nicht erschienen, Januar 2025

This book describes ways to invent and commercialize biomedicines in a more time and cost-efficient manner. Failure to translate a discovery into a marketed drug denies us an opportunity to improve the lives of patients who do not have access to effective therapies. Here, the authors provide a greater understanding of biopharmaceutical informatics.

Autor	Kumar, Sandeep (Hrsg.) / Nixon, Andrew (Hrsg.)
Verlag	Taylor & Francis
Einband	PDF
Erscheinungsjahr	2025
Seitenangabe	400 S.
Lieferstatus	Noch nicht erschienen, Januar 2025
Ausgabekennzeichen	Englisch
Abbildungen	24 schwarz-weiße und 36 farbige Abbildungen, 1 farbige Fotos, 24 schwarz-weiße und 35 farbige Zeichnungen, 26 schwarz-weiße Tabellen

Über den Autor Sandeep (Hrsg.) Kumar

Dr. Sandeep Kumar is a Distinguished Research Fellow (DRF) at the department of Biotherapeutics Discovery in Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. Sandeep Kumar holds a Ph.D. in Computational Biophysics and has over 20 years of experience researching protein structure - Function relationships using the computational means. Sandeep Kumar has so far contributed towards approximately 100 research articles, reviews, book chapters, and edited a book. He has also contributed towards development of several antibody-body based biotherapeutics and a vaccine currently in the market. After joining Boehringer-Ingelheim in 2018, Sandeep has been contributing towards discovery of several monoclonal antibodies as well as multi-specific modalities that are currently in development. Based on the insights gained from these experiences, Sandeep has been advocating for Biopharmaceutical Informatics, a strategic vision dedicated to synergistic use of computation and experimentation towards a cost effective and more efficient discovery and development of Biotherapeutics.Dr. Andrew Nixon is currently Vice President, Biotherapeutics Molecule Discovery at Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. Andy earned his Ph.D. in Physical Biochemistry from the University of London for studies completed at the MRC's National Institute for Medical Research. Andy has over 20 years of experience in biologic drug discovery and has contributed to over 100 antibody discovery programs resulting in numerous clinical candidates and approved biologics including TAKHZYRO, a fully human antibody inhibitor of plasma kallikrein.